BBO-8520 plus pembrolizumab showed a 75% ORR in 2L+ KRAS G12C inhibitor-experienced NSCLC. The company highlighted strategic focus on RAS-pathway malignancies and a strong balance sheet of $344.1 million.
BBO-8520 plus pembrolizumab showed a 75% ORR in 2L+ KRAS G12C inhibitor-experienced NSCLC. The company highlighted strategic focus on RAS-pathway malignancies and a strong balance sheet of $344.1 million.